Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications
Authors:
- Kenji MishiroKMKenji Mishiro
- Hirofumi HanaokaHHHirofumi Hanaoka
- Aiko YamaguchiAYAiko Yamaguchi
- Kazuma OgawaKazuma Ogawa
- 1 March 2019
- journal article
- review article
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 383, 104-131
Abstract
No abstract availableThis publication has 208 references indexed in Scilit:
- Lutetium-labelled peptides for therapy of neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Radiolabelled peptides for oncological diagnosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- PET Imaging of CXCR4 Receptors in Cancer by a New Optimized LigandChemMedChem, 2011
- Therapeutic efficacy of 177Lu‐CHX‐A″‐DTPA‐hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyThe Prostate, 2008
- Peptide-targeted radionuclide therapy for melanomaCritical Reviews in Oncology/Hematology, 2008
- Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMPEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out viewNuclear Medicine and Biology, 2007
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- Role of integrins in angiogenesisEuropean Journal of Cancer, 1996
- Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995